Fig. 4.

(A) Annualized ischemic stroke and (B) TE event rates after implantation vs expected (unadjusted) rates estimated based on the ${\mathrm{CHA}}_{\mathrm{2}}$${\mathrm{DS}}_{\mathrm{2}}$-${\mathrm{VAS}}_{\text{𝐜}}$ (congestive heart failure, hypertension, age $\mathrm{>}$75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65–74 years, sex category) score of the 3 study groups. DAPT, dual antiplatelet therapy; $R^{10}$, rivaroxaban 10 mg; $R^{15}$, rivaroxaban 15 mg; TE, thromboembolic.